Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CS-121 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Low Dose CS-121 | EXPERIMENTAL | Participants in this arm will receive a single low dose (0.5mg/kg) of CS-121. |
| Single Middle Dose CS-121 | EXPERIMENTAL | Participants in this arm will receive a single middle dose (0.7mg/kg) of CS-121. |
| Single High Dose CS-121 | EXPERIMENTAL | Participants in this arm will receive a single high dose (1.0mg/kg) of CS-121 |
| Single selected Lower Dose 1 of CS-121 | EXPERIMENTAL | Participants in this arm will receive a single selected lower dose 1 of CS-121. |
| Single selected Lower Dose 2 of CS-121 | EXPERIMENTAL | Participants in this arm will receive a single selected lower dose 2 of CS-121 |
| Name | Type | Description |
|---|---|---|
| CS-121 | BIOLOGICAL | CS-121 is a in vivo base editing therapy formulated in lipid nanoparticles for targeted editing of the APOC3 gene in hepatocytes. |
Inclusion Criteria: * Male or female participants aged 18 years ≤ age \< 65 years. * The serum triglyceride levels of the participants failed to be effectively controlled under the standard treatment regimen (or the medication that is available and tolerable as recommended by clinical practice) and...
CS-121 is an investigational monoclonal antibody being developed for the treatment of severe hypertriglyceridemia (sHTG), a metabolic condition characterized by extremely high levels of triglycerides in the blood. It is currently in early clinical development and has not been approved by regulatory authorities.
CS-121 is being developed by cbdMD, Inc., a company publicly traded under the ticker symbol YCBD. The drug is in Phase 1 clinical development for severe hypertriglyceridemia, with an ongoing clinical trial planned in China.
CS-121 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of severe hypertriglyceridemia, and its safety and efficacy have not yet been established.
CS-121 is being evaluated in a single early Phase 1 clinical trial registered as NCT07657780, titled 'CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia.' The trial is not yet recruiting and plans to enroll 15 participants with severe hypertriglyceridemia in China.
CS-121 is a monoclonal antibody, not a gene therapy. However, its clinical trial title references APOC3 base editing, which suggests the study may involve gene editing technology. The drug itself is classified as a monoclonal antibody modality for treating severe hypertriglyceridemia.